Comparative Pharmacology
Head-to-head clinical analysis: LODINE versus VOLTAREN XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LODINE versus VOLTAREN XR.
LODINE vs VOLTAREN-XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibition of prostaglandin synthesis via cyclooxygenase (COX) inhibition, with selectivity for COX-2 over COX-1.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. This leads to anti-inflammatory, analgesic, and antipyretic effects.
200 to 400 mg orally every 6 to 8 hours as needed; maximum daily dose 1200 mg.
100 mg orally once daily, extended-release formulation. Maximum 150 mg/day (divided as 75 mg twice daily or 100 mg once daily).
None Documented
None Documented
Terminal elimination half-life approximately 7.5 hours; in elderly or renal impairment, half-life may be prolonged up to 10 hours, requiring dose adjustment
The terminal elimination half-life is approximately 2 hours. The extended-release formulation (XR) does not alter the half-life; it maintains prolonged therapeutic plasma concentrations with twice-daily dosing.
Primarily renal (60% as metabolites, <1% unchanged); biliary/fecal (30-35%)
Approximately 65% of a dose is excreted renally as unchanged drug and metabolites (primarily as glucuronide conjugates); about 35% is eliminated via bile in feces.
Category C
Category C
NSAID
NSAID